JP2019516759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516759A5 JP2019516759A5 JP2018561557A JP2018561557A JP2019516759A5 JP 2019516759 A5 JP2019516759 A5 JP 2019516759A5 JP 2018561557 A JP2018561557 A JP 2018561557A JP 2018561557 A JP2018561557 A JP 2018561557A JP 2019516759 A5 JP2019516759 A5 JP 2019516759A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- cycloalkyl
- arbitrary
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*C([C@@](CC1)CN1c1cc2cccc(*)c2cn1)=O Chemical compound C*C([C@@](CC1)CN1c1cc2cccc(*)c2cn1)=O 0.000 description 2
- RKWSMOBCWOSVOU-UHFFFAOYSA-N CC(C)[n]1c(cccc2)c2c(-c2n[n](C)c(CC3)c2CN3C(C)=O)c1 Chemical compound CC(C)[n]1c(cccc2)c2c(-c2n[n](C)c(CC3)c2CN3C(C)=O)c1 RKWSMOBCWOSVOU-UHFFFAOYSA-N 0.000 description 1
- GSGFUJNUHRGDLF-UHFFFAOYSA-O CC(N(CC1)CC(C(c(c2c3ccnc2)ccc3F)=[NH2+])=C1NC1CCOCC1)=O Chemical compound CC(N(CC1)CC(C(c(c2c3ccnc2)ccc3F)=[NH2+])=C1NC1CCOCC1)=O GSGFUJNUHRGDLF-UHFFFAOYSA-O 0.000 description 1
- WZEAWVAERAAIEX-UHFFFAOYSA-O CC(N(CC1)CC(C(c(cc2)c(cncc3)c3c2Cl)=[NH2+])=C1NC1CCOCC1)=O Chemical compound CC(N(CC1)CC(C(c(cc2)c(cncc3)c3c2Cl)=[NH2+])=C1NC1CCOCC1)=O WZEAWVAERAAIEX-UHFFFAOYSA-O 0.000 description 1
- WIXFKVSMBGUBTA-IBGZPJMESA-N CC(N(CC1)CC(C(c2c(C)[nH]c3c2ccc(-c2c[n](C)nc2)c3)=N)=C1N[C@@H]1COCC1)=O Chemical compound CC(N(CC1)CC(C(c2c(C)[nH]c3c2ccc(-c2c[n](C)nc2)c3)=N)=C1N[C@@H]1COCC1)=O WIXFKVSMBGUBTA-IBGZPJMESA-N 0.000 description 1
- QSUIOQYCNLHTQS-RWENNGKJSA-N CC(N(CC1)CC(C(c2c(C)[nH]c3c2ccc(/C(/CN)=C/NC)c3)=N)=C1NC1COCC1)=O Chemical compound CC(N(CC1)CC(C(c2c(C)[nH]c3c2ccc(/C(/CN)=C/NC)c3)=N)=C1NC1COCC1)=O QSUIOQYCNLHTQS-RWENNGKJSA-N 0.000 description 1
- JHLUQWDELJFYRE-UHFFFAOYSA-O CC(N(CC1)CC(C(c2c(cnc(N3CCCC3)c3)c3ccc2)=[NH2+])=C1NC1CCOCC1)=O Chemical compound CC(N(CC1)CC(C(c2c(cnc(N3CCCC3)c3)c3ccc2)=[NH2+])=C1NC1CCOCC1)=O JHLUQWDELJFYRE-UHFFFAOYSA-O 0.000 description 1
- AGWQHAZGGMNEOF-UHFFFAOYSA-O CC(N(CC1)CC(C(c2c[nH]c(cc3)c2cc3-c2c[n](C)nc2)=[NH2+])=C1NC)=O Chemical compound CC(N(CC1)CC(C(c2c[nH]c(cc3)c2cc3-c2c[n](C)nc2)=[NH2+])=C1NC)=O AGWQHAZGGMNEOF-UHFFFAOYSA-O 0.000 description 1
- IWHQCMQFHRHPNR-UHFFFAOYSA-O CC(N(CC1)CC(C(c2cc(-c3c[n](C)nc3)ccc2)=[NH2+])=C1NC)=O Chemical compound CC(N(CC1)CC(C(c2cc(-c3c[n](C)nc3)ccc2)=[NH2+])=C1NC)=O IWHQCMQFHRHPNR-UHFFFAOYSA-O 0.000 description 1
- JKNCXBMKAJLWHN-UHFFFAOYSA-O CC(N(CC1)CC(C(c2ccc(C)c3c2cc[nH]3)=[NH2+])=C1NC)=O Chemical compound CC(N(CC1)CC(C(c2ccc(C)c3c2cc[nH]3)=[NH2+])=C1NC)=O JKNCXBMKAJLWHN-UHFFFAOYSA-O 0.000 description 1
- IXQWNXJLNOFSRE-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2-c(c1c2[nH]cc1)ccc2Cl)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2-c(c1c2[nH]cc1)ccc2Cl)=O IXQWNXJLNOFSRE-UHFFFAOYSA-N 0.000 description 1
- HWPHUYSBHLYXFP-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2-c1c(cc[nH]2)c2cc(C(OC)=O)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2-c1c(cc[nH]2)c2cc(C(OC)=O)c1)=O HWPHUYSBHLYXFP-UHFFFAOYSA-N 0.000 description 1
- RMTJHTPDLSMGNR-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2-c1c(cc[nH]2)c2cc(OC)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2-c1c(cc[nH]2)c2cc(OC)c1)=O RMTJHTPDLSMGNR-UHFFFAOYSA-N 0.000 description 1
- YAOPYMWNGQHROH-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2-c1c(cc[nH]2)c2ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2-c1c(cc[nH]2)c2ccc1)=O YAOPYMWNGQHROH-UHFFFAOYSA-N 0.000 description 1
- XGLAIMCDIMBGPK-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c(c1c2ccnc1)ccc2OC)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c(c1c2ccnc1)ccc2OC)=O XGLAIMCDIMBGPK-UHFFFAOYSA-N 0.000 description 1
- QRHSMFNSBKWHNZ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c(c1cnc2)cccc1c2Cl)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c(c1cnc2)cccc1c2Cl)=O QRHSMFNSBKWHNZ-UHFFFAOYSA-N 0.000 description 1
- GAVVBDXGDAIREU-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c(c1cnc2)cccc1c2OC)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c(c1cnc2)cccc1c2OC)=O GAVVBDXGDAIREU-UHFFFAOYSA-N 0.000 description 1
- DXDMNVZXOSKMBM-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(C)[nH]c2c1cccc2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(C)[nH]c2c1cccc2)=O DXDMNVZXOSKMBM-UHFFFAOYSA-N 0.000 description 1
- VTCVXJOJHKXFNH-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(-c2c[n](C)nc2)c2)c2cc(C)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(-c2c[n](C)nc2)c2)c2cc(C)c1)=O VTCVXJOJHKXFNH-UHFFFAOYSA-N 0.000 description 1
- VCCZELIPLFSVQC-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(-c2c[n](C)nc2)c2)c2ccc1C)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(-c2c[n](C)nc2)c2)c2ccc1C)=O VCCZELIPLFSVQC-UHFFFAOYSA-N 0.000 description 1
- DJSHZSFSVVWRLV-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(N(CC2)CC2C#N)c2)c2ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(N(CC2)CC2C#N)c2)c2ccc1)=O DJSHZSFSVVWRLV-UHFFFAOYSA-N 0.000 description 1
- MURDGIZINCTSAI-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(N2CCCCC2)c2)c2ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(N2CCCCC2)c2)c2ccc1)=O MURDGIZINCTSAI-UHFFFAOYSA-N 0.000 description 1
- FXGWPWRNOMGUEL-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(N2CCN(C)CC2)c2)c2ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(N2CCN(C)CC2)c2)c2ccc1)=O FXGWPWRNOMGUEL-UHFFFAOYSA-N 0.000 description 1
- UHNWSNQEYDVJCQ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cncc2)c2c(CO)cc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cncc2)c2c(CO)cc1)=O UHNWSNQEYDVJCQ-UHFFFAOYSA-N 0.000 description 1
- IZPACEJNRRRHNL-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cncc2C=C)c2ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cncc2C=C)c2ccc1)=O IZPACEJNRRRHNL-UHFFFAOYSA-N 0.000 description 1
- VEGQMQNNMPHWTC-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c[nH]c2c1cccc2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c[nH]c2c1cccc2)=O VEGQMQNNMPHWTC-UHFFFAOYSA-N 0.000 description 1
- IUALVYSGFLFDGK-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c[n](C)c2c1cccc2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c[n](C)c2c1cccc2)=O IUALVYSGFLFDGK-UHFFFAOYSA-N 0.000 description 1
- JEJLXAUUWSWJGH-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cc(Cl)cc2c1cnc(-c1c[n](C)nc1)c2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cc(Cl)cc2c1cnc(-c1c[n](C)nc1)c2)=O JEJLXAUUWSWJGH-UHFFFAOYSA-N 0.000 description 1
- YMJZTJARHXMQNO-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1ccc(C)c2c1cncc2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1ccc(C)c2c1cncc2)=O YMJZTJARHXMQNO-UHFFFAOYSA-N 0.000 description 1
- XJAYQWZRDYTMBJ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cccc2c(C)c(-c3c[n](C)nc3)ncc12)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cccc2c(C)c(-c3c[n](C)nc3)ncc12)=O XJAYQWZRDYTMBJ-UHFFFAOYSA-N 0.000 description 1
- HPNNACJOXIUFQN-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cccc2c(CO)cncc12)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cccc2c(CO)cncc12)=O HPNNACJOXIUFQN-UHFFFAOYSA-N 0.000 description 1
- YKJCGHAYZPQUNB-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cccc2c1[nH]cc2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cccc2c1[nH]cc2)=O YKJCGHAYZPQUNB-UHFFFAOYSA-N 0.000 description 1
- DBRHAVKKINQCFP-DLKOBCSISA-N CC(N(CC1)Cc2c1[n](C1COC1)nc2-c1c[nH]c2c1ccc(/C(/C=N)=C/NC)c2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COC1)nc2-c1c[nH]c2c1ccc(/C(/C=N)=C/NC)c2)=O DBRHAVKKINQCFP-DLKOBCSISA-N 0.000 description 1
- VJMYKALJTHINKT-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2-c1c[nH]c2c1ccc(-c1c[n](C)nc1)c2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2-c1c[nH]c2c1ccc(-c1c[n](C)nc1)c2)=O VJMYKALJTHINKT-UHFFFAOYSA-N 0.000 description 1
- MPXKOIKIRQBXKT-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](CC1CC1)nc2-c1c(cc[nH]2)c2ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](CC1CC1)nc2-c1c(cc[nH]2)c2ccc1)=O MPXKOIKIRQBXKT-UHFFFAOYSA-N 0.000 description 1
- RWGXTFKQGCEQMJ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](CC1CC1)nc2-c1c[nH]c2c1cccc2)=O Chemical compound CC(N(CC1)Cc2c1[n](CC1CC1)nc2-c1c[nH]c2c1cccc2)=O RWGXTFKQGCEQMJ-UHFFFAOYSA-N 0.000 description 1
- YSSFCOVCRFYODP-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](CC1CC1)nc2-c1ccc(C)c2c1cc[nH]2)=O Chemical compound CC(N(CC1)Cc2c1[n](CC1CC1)nc2-c1ccc(C)c2c1cc[nH]2)=O YSSFCOVCRFYODP-UHFFFAOYSA-N 0.000 description 1
- UEFJFQPLVYIOOV-SFHVURJKSA-N CC(N(CC1)Cc2c1[n]([C@@H]1COCC1)nc2-c1cccc2c1ccc(-c1c[n](C)nc1)n2)=O Chemical compound CC(N(CC1)Cc2c1[n]([C@@H]1COCC1)nc2-c1cccc2c1ccc(-c1c[n](C)nc1)n2)=O UEFJFQPLVYIOOV-SFHVURJKSA-N 0.000 description 1
- GHQQSOMXAFNIIX-UHFFFAOYSA-O CCc1c(cccc2C(C(CN(CC3)C(C)=O)=C3NC3CCOCC3)=[NH2+])c2cnc1 Chemical compound CCc1c(cccc2C(C(CN(CC3)C(C)=O)=C3NC3CCOCC3)=[NH2+])c2cnc1 GHQQSOMXAFNIIX-UHFFFAOYSA-O 0.000 description 1
- LDVUEFAKDIGXQX-UHFFFAOYSA-N CCc1ccc(-c2n[n](C3CCOCC3)c(CC3)c2CN3C(C)=O)c2c1ccnc2 Chemical compound CCc1ccc(-c2n[n](C3CCOCC3)c(CC3)c2CN3C(C)=O)c2c1ccnc2 LDVUEFAKDIGXQX-UHFFFAOYSA-N 0.000 description 1
- FAQWKGYIDUQQEE-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](C1CCOCC1)c(C#N)c2C(CC=Cc1c2)c1cnc2-c1c[n](CCNC(N(CC2)Cc3c2[n](C2CCOCC2)nc3-c2c(CCCN(C3)c4c[n](C)nc4)c3ccc2)=O)nc1)=O Chemical compound CNC(N(CC1)Cc2c1[n](C1CCOCC1)c(C#N)c2C(CC=Cc1c2)c1cnc2-c1c[n](CCNC(N(CC2)Cc3c2[n](C2CCOCC2)nc3-c2c(CCCN(C3)c4c[n](C)nc4)c3ccc2)=O)nc1)=O FAQWKGYIDUQQEE-UHFFFAOYSA-N 0.000 description 1
- DRWVHZPKNZHPFP-UHFFFAOYSA-N COc(cc1)ccc1N(Cc1c2c(I)ccc1)C2=O Chemical compound COc(cc1)ccc1N(Cc1c2c(I)ccc1)C2=O DRWVHZPKNZHPFP-UHFFFAOYSA-N 0.000 description 1
- NZOVMAWNOOEQJP-UHFFFAOYSA-N C[n]1ncc(N(CCc(c2ccc3)c3[IH]C)C2=O)c1 Chemical compound C[n]1ncc(N(CCc(c2ccc3)c3[IH]C)C2=O)c1 NZOVMAWNOOEQJP-UHFFFAOYSA-N 0.000 description 1
- RZLGPVWNRCQORH-UHFFFAOYSA-N C[n]1ncc(N(Cc2ccccc2C2)C2=O)c1 Chemical compound C[n]1ncc(N(Cc2ccccc2C2)C2=O)c1 RZLGPVWNRCQORH-UHFFFAOYSA-N 0.000 description 1
- IPWVATCRLKASLP-UHFFFAOYSA-N Cc(c1ccc2)c(-c3c[n](C)nc3)ncc1c2-c1n[n](C2CCOCC2)c(CC2)c1CN2C(NC)=O Chemical compound Cc(c1ccc2)c(-c3c[n](C)nc3)ncc1c2-c1n[n](C2CCOCC2)c(CC2)c1CN2C(NC)=O IPWVATCRLKASLP-UHFFFAOYSA-N 0.000 description 1
- MQPVQCUKTCDLKI-UHFFFAOYSA-N Cc1c(CC(N(C)C2)=O)c2ccc1 Chemical compound Cc1c(CC(N(C)C2)=O)c2ccc1 MQPVQCUKTCDLKI-UHFFFAOYSA-N 0.000 description 1
- TZPZTDFDCDHPHG-UHFFFAOYSA-N Cc1cccc2c1cnc(-c(cc1)cnc1C(NC)=O)c2F Chemical compound Cc1cccc2c1cnc(-c(cc1)cnc1C(NC)=O)c2F TZPZTDFDCDHPHG-UHFFFAOYSA-N 0.000 description 1
- PSBDRZJULJXNAT-UHFFFAOYSA-N N#Cc1cc(NC(c2cccc(I)c2)=O)ccc1 Chemical compound N#Cc1cc(NC(c2cccc(I)c2)=O)ccc1 PSBDRZJULJXNAT-UHFFFAOYSA-N 0.000 description 1
- QRKLKNHKYLIORU-UHFFFAOYSA-N O=C(Cc1c(C2)cccc1I)N2C1CCCC1 Chemical compound O=C(Cc1c(C2)cccc1I)N2C1CCCC1 QRKLKNHKYLIORU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/083118 | 2016-05-24 | ||
| CN2016083118 | 2016-05-24 | ||
| PCT/US2017/034326 WO2017205538A1 (en) | 2016-05-24 | 2017-05-24 | Pyrazolopyridine derivatives for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516759A JP2019516759A (ja) | 2019-06-20 |
| JP2019516759A5 true JP2019516759A5 (https=) | 2020-07-02 |
| JP7014736B2 JP7014736B2 (ja) | 2022-02-01 |
Family
ID=59055277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561557A Expired - Fee Related JP7014736B2 (ja) | 2016-05-24 | 2017-05-24 | がんの処置のためのピラゾロピリジン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11247989B2 (https=) |
| EP (1) | EP3464286B1 (https=) |
| JP (1) | JP7014736B2 (https=) |
| CN (1) | CN109476663B (https=) |
| MA (1) | MA45146A (https=) |
| WO (1) | WO2017205538A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| AU2019245403B2 (en) * | 2018-03-29 | 2025-02-06 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| CN110878042B (zh) * | 2018-09-05 | 2021-06-01 | 新发药业有限公司 | 一种n-取代基哌啶-3-酮的制备方法 |
| CN111320621B (zh) * | 2018-12-14 | 2022-10-04 | 中国科学院广州生物医药与健康研究院 | 一种吲嗪类化合物及其制备方法和应用 |
| CN113646002A (zh) * | 2019-02-27 | 2021-11-12 | 上海睿跃生物科技有限公司 | 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法 |
| SMT202400386T1 (it) * | 2019-02-27 | 2024-11-15 | Constellation Pharmaceuticals Inc | Derivati di n-(piridinil)acetammide come inibitori di hat p300/cbp e metodi per il loro utilizzo |
| KR20220018475A (ko) * | 2019-04-09 | 2022-02-15 | 플렉시콘 인코퍼레이티드 | Ep300 또는 cbp 조절 및 이의 표시를 위한 응축 아진 |
| EP4005638A4 (en) | 2019-07-29 | 2023-07-05 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| TW202120095A (zh) * | 2019-08-05 | 2021-06-01 | 美商美國禮來大藥廠 | 7,8-二氫-4H-吡唑并[4,3-c]氮呯-6-酮化合物 |
| US20230131192A1 (en) * | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| CN111440161B (zh) * | 2020-05-15 | 2023-04-14 | 中国药科大学 | 一种具有par4拮抗活性的二环杂芳基类化合物及其应用 |
| WO2021248382A1 (zh) * | 2020-06-10 | 2021-12-16 | 北京小米移动软件有限公司 | 生物特征的验证方法及装置、电子设备及存储介质 |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| SMT202500271T1 (it) | 2020-07-02 | 2025-09-12 | Incyte Corp | Composti di urea triciclici come inibitori di v617f di jak2 |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| CN112079826B (zh) * | 2020-09-17 | 2022-07-29 | 广州中医药大学(广州中医药研究院) | 一类甾体合成酶抑制剂及其治疗应用 |
| WO2022072648A1 (en) | 2020-10-02 | 2022-04-07 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| JP7777131B2 (ja) | 2020-10-02 | 2025-11-27 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 転写活性化タンパク質のイミダゾピペラジン阻害剤 |
| WO2022093817A1 (en) * | 2020-10-26 | 2022-05-05 | Yale University | Macrophage migration inhibitory factor inhibitors, and methods of making and using same |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| FI4426434T3 (fi) | 2021-11-02 | 2025-11-24 | Flare Therapeutics Inc | Pparg:n käänteisagonisteja ja niiden käyttöjä |
| CR20240191A (es) | 2021-11-12 | 2024-09-13 | Insilico Medicine Ip Ltd | Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos |
| CN119173514A (zh) | 2022-03-17 | 2024-12-20 | 因赛特公司 | 作为jak2 v617f抑制剂的三环脲化合物 |
| JP2025524870A (ja) | 2022-07-18 | 2025-08-01 | Jsr株式会社 | α，β不飽和カルボニル化合物およびそれらの中間体の光触媒合成 |
| CN117843618A (zh) * | 2022-08-29 | 2024-04-09 | 北京沐华生物科技有限责任公司 | 一种ep300/cbp调节剂及其制备方法和用途 |
| CN115710249B (zh) * | 2022-11-14 | 2024-11-19 | 广东工业大学 | 一种多取代异喹啉和1,6-萘啶化合物的制备方法及光电材料常见分子骨架 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| DK27383A (da) * | 1982-02-17 | 1983-08-18 | Lepetit Spa | Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| EP0659439B1 (en) | 1993-12-24 | 2001-10-24 | MERCK PATENT GmbH | Immunoconjugates |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| PL179659B1 (pl) | 1994-07-21 | 2000-10-31 | Akzo Nobel Nv | Kompozycja cyklicznych nadtlenków ketonów sluzaca do modyfikowania (ko)polimerów zwlaszcza do degradacji polipropylenu PL PL PL PL PL PL PL |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| MX9707453A (es) | 1995-03-30 | 1997-12-31 | Pfizer | Derivados de quinazolina. |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ATE241986T1 (de) | 1997-05-06 | 2003-06-15 | Wyeth Corp | Verwendung von chinazolin verbindungen zur behandlung von polyzystischer nierenkrankheit |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| CN1278176A (zh) | 1997-11-06 | 2000-12-27 | 美国氰胺公司 | 喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用 |
| WO2000031048A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| CA2493625A1 (en) | 2002-07-25 | 2004-02-19 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| JP2005537290A (ja) | 2002-07-25 | 2005-12-08 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物 |
| MXPA05009719A (es) | 2003-03-11 | 2005-10-18 | Pharmacia Italia Spa | Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US7947686B2 (en) | 2005-12-12 | 2011-05-24 | Nerviano Medical Sciences S.R.L. | Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors |
| WO2007099166A1 (en) | 2006-03-03 | 2007-09-07 | Nerviano Medical Sciences S.R.L. | Pyrazolo-pyridine derivatives active as kinase inhibitors |
| WO2009084693A1 (ja) | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | 抗癌剤 |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CL2009001158A1 (es) | 2008-05-15 | 2009-10-23 | Nerviano Medical Sciences Srl | Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer. |
| JP5433690B2 (ja) | 2008-06-25 | 2014-03-05 | ブリストル−マイヤーズ スクイブ カンパニー | 抗−ｈｉｖ薬としてのジケト縮合アゾロピペリジンおよびアゾロピペラジン |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| CN101812063B (zh) | 2010-03-18 | 2012-04-25 | 中国医学科学院医药生物技术研究所 | α-萘磺酰胺基五元杂环类化合物及其抑瘤活性 |
| KR20140075723A (ko) | 2011-09-12 | 2014-06-19 | 사노피 | 인다닐-치환된 4,5,6,7-테트라하이드로-1H-피라졸로[4,3,c]피리딘, 약물로서 그의 용도, 및 그를 포함한 약제학적 제제 |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| WO2013148114A1 (en) | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| WO2014138727A1 (en) | 2013-03-08 | 2014-09-12 | Board Of Regents, The University Of Texas System | Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein c receptors (epcr) |
| EP2993174A1 (en) * | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| US9763922B2 (en) | 2014-11-27 | 2017-09-19 | Genentech, Inc. | Therapeutic compounds and uses thereof |
-
2017
- 2017-05-24 EP EP17729963.3A patent/EP3464286B1/en active Active
- 2017-05-24 WO PCT/US2017/034326 patent/WO2017205538A1/en not_active Ceased
- 2017-05-24 CN CN201780045658.6A patent/CN109476663B/zh active Active
- 2017-05-24 JP JP2018561557A patent/JP7014736B2/ja not_active Expired - Fee Related
- 2017-05-24 MA MA045146A patent/MA45146A/fr unknown
-
2018
- 2018-11-21 US US16/198,581 patent/US11247989B2/en not_active Expired - Fee Related
-
2022
- 2022-01-06 US US17/570,139 patent/US20220127265A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516759A5 (https=) | ||
| JP2019516757A5 (https=) | ||
| JP2017530176A5 (https=) | ||
| JP2017533250A5 (https=) | ||
| JP2018510851A5 (https=) | ||
| JP2017537100A5 (https=) | ||
| JP2017526696A5 (https=) | ||
| AU2013214783B2 (en) | CDK8/CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer | |
| JP2017533249A5 (https=) | ||
| JP6066421B2 (ja) | 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法 | |
| JP2017533248A5 (https=) | ||
| JP6835472B2 (ja) | 癌の処置のための組成物 | |
| JP2017525740A5 (https=) | ||
| JP2018501287A5 (https=) | ||
| JP2017530984A5 (https=) | ||
| CN103458896B (zh) | 用于治疗癌症的方法 | |
| JP2018505169A5 (https=) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2009541223A5 (https=) | ||
| HRP20160056T1 (hr) | Metode za lijeäśenje tumora koristeä†i 3-(5-amino-2-metil-4-okso-4h-kinazolin-3-il)piperidin-2,6-dion | |
| JP2018507191A5 (https=) | ||
| JP2015514796A5 (https=) | ||
| CN104470509A (zh) | 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途 | |
| CN104755455A (zh) | 可用于治疗癌症的巨大戟醇衍生化合物 | |
| RU2011139157A (ru) | Производное трициклического пиразолопиримидина |